PathMaker Neurosystems Inc. announces establishment of European operations at the iPEPS-ICM bioincubator at the Brain and Spine Institute (ICM) in Paris, France
Paris, France and Boston, MA (June 22, 2015) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing novel non-invasive systems for the treatment of neuromotor disorders, today announced that it has established European operations at the iPEPS-ICM bioincubator at the Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) at the Pitié-Salpêtrière Hospital in Paris, the largest neurological hospital in France.
The Brain and Spine Institute is an international center of excellence focused on research into neurological diseases, employing over 600 physicians and scientific researchers who are among the most highly regarded in the world. The iPEPS-ICM bioincubator was established to accelerate the transformation of breakthrough ideas in the neuroscience field into innovative products by furnishing an environment ideal for the development and commercialization of novel technologies. “We are pleased to welcome PathMaker Neurosystems, an innovative company active in the field of neuromodulation that is collaborating with researchers from our institute,” said Alexis Genin, Ph.D., Head of Research and Technology Development at ICM. “We look forward to working with PathMaker as they advance their novel tsDCS-based technology into clinical trials.”
“We are delighted to have been selected to join the iPEPS-ICM bioincubator,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “By establishing our European office and operations at France’s leading neurological research institution, we not only will be able to work closely with leading specialists and researchers, but will also be able to utilize core research facilities and the specialized Clinical Investigation Centre at ICM.”
PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our Company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, dgoncalves@tizinc.com
About Brain and Spine Institute
The Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) in Paris, France is a world-class research establishment cofounded by private benefactors and French public institutions such as Inserm, CNRS, APHP and UPMC. It is innovative in both its conception and its organization. By bringing together patients, doctors and researchers under the same roof, it aims to facilitate the rapid development of treatments for diseases of the nervous system so that they can be applied to patients as quickly as possible. The center has the best scientists from every domain and every country and they are conducting groundbreaking research in this area. From a scientific standpoint, the ICM’s approach is novel to the extent that its research is decompartmentalized. Its 25 research teams work independently but are associated along thematic lines that encourage the pooling of expertise and the implementation of joint projects. Bringing together patients, doctors and researchers under one roof facilitates the conduct of both fundamental and clinical research, ultimately shortening the lead time from research to therapeutics for the great benefit of patients. For more information, please visit http://www.icm-institute.org.